RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
RECURSION PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.61+0.15 (+4.18%)
Close on Oct 19, 2026
- Market cap
- $1.92B
- P/E (TTM)
- –
- Dividend yield
- –
RECURSION PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operating revenue | $74.26M | $58.49M | $43.88M | $39.68M | $10.00M | $3.41M | $1.71M | 99.4% | +27.0% |
| Grant revenue | $425.00K | $351.00K | $699.00K | $162.00K | $178.00K | $549.00K | $608.00K | 0.6% | +21.1% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $39.34M | $57.38M | $43.81M | – | – | – | – | 52.7% | -31.4% |
| United Kingdom | $35.34M | $1.14M | $0 | – | – | – | – | 47.3% | +3013.4% |
| Other | $0 | $327.00K | $769.00K | – | – | – | – | 0.0% | -100.0% |
From the segment and revenue-disaggregation notes of Recursion Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.